Popular terms

Autoimmune topics
Autoimmune
Immune Disease
Autoimmune Disease
Immune Diseases
Autoimmune Diseases
Transplant
Immune Disorder
Autoimmune Disorder
Autoimmune Disorders
Infectious
Infectious Disease
Inflammatory Disease
Type 1 Diabetes
Proliferative Disorder
Recurrence

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Autoimmune patents



      

This page is updated frequently with new Autoimmune-related patent applications.




Date/App# patent app List of recent Autoimmune-related patents
07/21/16
20160208217 
 Method for enhancing therapeutic effect of stem cells on autoimmune diseases, cardiovascular diseases, and/or hematological diseases patent thumbnailnew patent Method for enhancing therapeutic effect of stem cells on autoimmune diseases, cardiovascular diseases, and/or hematological diseases
A method for enhancing the therapeutic effect of stem cells on autoimmune diseases, cardiovascular diseases, and/or hematological diseases is provided. The method comprises pre-treating the stem cells with ligustilide to increase the expression of differentiation-promoting genes in the stem cells, increase the expression of homing-promoting genes in the stem cells, and/or decrease the expression of inflammatory genes in the stem cells, wherein the treatment is conducted in a culture medium of the stem cell..
Gwo Xi Stem Cell Applied Technology Co., Ltd.


07/21/16
20160208013 
 Methods and compositions for reducing cardiac damage and other conditions patent thumbnailnew patent Methods and compositions for reducing cardiac damage and other conditions
Endoglin has been identified to play a functional role as a regulator of tgfβ1 signaling, particular in tgfβ1-mediated calcineurin expression. The present invention features methods of reducing cardiac damage, particularly in a subject undergoing chemotherapy or radiation therapy by administering a composition that inhibits endoglin activity.
Tufts Medical Center, Inc.


07/21/16
20160208010 
 Anti-human cd52 immunoglobulins patent thumbnailnew patent Anti-human cd52 immunoglobulins
The present invention relates to humanized immunoglobulins, mouse monoclonal antibodies and chimeric antibodies that have binding specificity for human cd52. The present invention further relates to a humanized immunoglobulin light chain and a humanized immunoglobulin heavy chain.
Genzyme Corporation


07/21/16
20160207949 
 Novel cytotoxic agents for conjugation to a cell binding molecule patent thumbnailnew patent Novel cytotoxic agents for conjugation to a cell binding molecule
The present invention is related to novel cytotoxic agents, pyrrolo[2,1-c][1,4]benzodiazepine (pbd) derivatives, their conjugates with a cell-binding agent, the preparation and the therapeutic uses in the targeted treatment of cancers, autoimmune disorders, and infectious diseases.. .
Hangzhou Dac Biotech Co., Ltd


07/21/16
20160206756 
 Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein patent thumbnailnew patent Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
The present application describes a coding nucleic acid sequence, particularly a messenger rna (mrna), comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal and the use thereof for increasing the expression of an encoded protein. It also discloses its use for the preparation of a pharmaceutical composition, especially a vaccine e.g.
Curevac Ag


07/21/16
20160206666 
 Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tighten gut mucosal barrier patent thumbnailnew patent Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tighten gut mucosal barrier
Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of treating or preventing autoimmune disorders, inhibiting inflammatory mechanisms in the gut, and/or tightening gut mucosal barrier function are disclosed.. .
Synlogic, Inc.


07/21/16
20160206660 
 Composition of stem cells having highly expressed fas ligand patent thumbnailnew patent Composition of stem cells having highly expressed fas ligand
This disclosure relates in general to a stem cell treatment. This disclosure further relates to a stem cell treatment using a composition comprising stem cells having highly expressed fas-l.
University Of Southern California


07/21/16
20160206611 
 Apoptosis-induced agents for the treatment of cancer and immune and autoimmune diseases patent thumbnailnew patent Apoptosis-induced agents for the treatment of cancer and immune and autoimmune diseases
Disclosed are compounds which inhibit the activity of anti-apoptotic bcl-xl proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic bcl-xl protein.. .
Abbvie Inc.


07/21/16
20160206595 
 Indole-3-aldehyde for treating dysreactive immune disorders patent thumbnailnew patent Indole-3-aldehyde for treating dysreactive immune disorders
The therapeutic use of bacteria, specifically but not only lactobacilli, which produce indole-3-aldehyde, or directly of indole-3-aldehyde itself, is proposed as a means of prevention and treatment of immune dysreactive disorders in which the hyper-inflammatory or autoimmune component represents the basic element. .
Universita' Degli Studi Di Perugia


07/21/16
20160206587 
 Pharmaceutical composition containing dimethyl fumarate for administration at a low daily dose patent thumbnailnew patent Pharmaceutical composition containing dimethyl fumarate for administration at a low daily dose
The present invention relates to pharmaceutical compositions containing dimethyl fumarate (dmf), more specifically, the present invention relates to a pharmaceutical composition for oral use in treating hyperproliferative, inflammatory or autoimmune disorders by administering a low daily dosage in the range of 410 mg±5% or 400 mg±5% dimethyl fumarate, wherein the pharmaceutical formulation is in the form of an erosion matrix tablet.. .
Forward Pharma A/s


07/21/16
20160206578 
new patent

Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use


The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-phenyl-sulfonamido-cycloalkyl compounds of the following formula (collectively referred to herein as “apsac compounds”). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, in treatment, for example, of inflammation and/or joint destruction and/or bone loss; of disorders mediated by excessive and/or inappropriate and/or prolonged activation of the immune system; of inflammatory and autoimmune disorders, for example, rheumatoid arthritis, psoriasis, psoriatic arthritis, chronic obstructive pulmonary disease (copd), atherosclerosis, inflammatory bowel disease, ankylosing spondylitis, and the like; of disorders associated with bone loss, such as bone loss associated with excessive osteoclast activity in rheumatoid arthritis, osteoporosis, cancer-associated bone disease, paget's disease and the like, etc.; and of cancer, such as a haematological malignancy, a solid tumour, etc..
Pimco 2664 Limited


07/14/16
20160201133 

Methods of monitoring conditions by sequence analysis


There is a need for improved methods for determining the diagnosis and prognosis of patients with conditions, including autoimmune disease and cancer. Provided herein are methods for using dna sequencing to identify personalized biomarkers in patients with autoimmune disease and other conditions.
Adaptive Biotechnologies Corp.


07/14/16
20160201060 

Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response


The invention provides immune regulatory oligonucleotides (iro) as antagonist of tlrs and methods of use thereof. These iros have unique sequences that inhibit tlr-mediated signaling in response to a tlr ligand or tlr agonist.
Idera Pharmaceuticals, Inc.


07/14/16
20160200807 

Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use


The disclosure provides anti-myostatin antibodies and methods of making and using the same. Nucleic acids encoding the anti-myostatin antibodies and host cells comprising the nucleic acids are also provided.
Chugai Seiyaku Kabushiki Kaisha


07/14/16
20160200789 

Il4 conjugated to antibodies against extracellular matrix components


A conjugate comprising interleukin-4 (il4) and a specific binding member is disclosed. The specific binding member preferably binds an extra-cellular matrix component associated with neoplastic growth and/or angiogenesis, and the conjugate may be used for targeting il4 to tissues in vivo.
Philogen S.p.a.


07/14/16
20160200730 

Polyfluorinated compounds acting as bruton tyrosine kinase inhibitors


Described herein is a novel series of multi-fluoro-substituted pyrazolopyrimidine compounds or salts thereof. These compounds are bruton's tyrosine kinase (btk) inhibitors.
Zhejiang Dtrm Biopharma Co. Ltd.


07/14/16
20160200724 

Dihydropyrrolopyridine inhibitors of ror-gamma


Pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by rorγ. Also provided are pharmaceutical compositions comprising the novel compounds of formula (i) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders..

07/14/16
20160200710 

Carbazole carboxamide compounds


Disclosed are compounds of formula (i); and salts thereof, wherein: formula (ii); q is: r1 is —c(ch3)2oh, —nhc(=0)c(ch3)3, —n(ch3)2, or —ch2rd; r2 is ci or —ch3; r3 is h, f, or —ch3; ra is h or —ch3; rb is h, f, ci, or —och3 rc is h or f; and rd is —oh, —och3, —nhc(=0)ch3, or formula (iii), also disclosed are methods of using such compounds as inhibitors of bruton's tyrosine kinase (btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease..
Bristol-myers Squibb Company


07/14/16
20160200674 

Ido inhibitors


There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (ido), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or autoimmune diseases utilizing the compounds of the invention.. .
Bristol-myers Squibb Company


07/14/16
20160199346 

Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof


The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.. .
Orbital Atk, Inc.


07/07/16
20160194712 

Mirna based treatment monitoring in autoimmune diseases


The invention relates to methods of determining whether a patient responds to a therapeutic treatment of an autoimmune disease, of monitoring the course of an autoimmune disease in a patient, of determining the risk for a relapse of an autoimmune disease in a patient, and of adjusting the dose of a therapeutic drug applied for therapeutic treatment of an autoimmune disease in a patient. Said methods are based on the determination of the level of at least one mirna in a test sample isolated from the patient.
Comprehensive Biomarker Center Gmbh


07/07/16
20160194642 

Spherical nucleic acid-based constructs as immunoregulatory agents


Aspects of the invention relate to nanoscale constructs and related methods and compositions thereof. The compositions of the invention are useful for treating disorders that are sensitive to levels of immune cell activation, such as autoimmune disease or other inflammation based disease or disorder..
Exicure, Inc


07/07/16
20160194403 

Modulation of gamma delta t cells


The present invention relate to the discovery that btla, il-7 and rorγt modulate the activity and expression of γδt cells. Specifically, the present invention provides methods of modulating γδt cell homeostasis and function by regulating expression of btla.
Sanford-burnham Medical Research Institute


07/07/16
20160194397 

Fc receptor binding proteins


This disclosure provides, inter alia, proteins that bind to fcrn, e.g., immunoglobulins that inhibit fcrn with high affinity and selectivity. The fcrn-binding proteins can be used to treat a variety of disorders including autoimmune disorders..
Biogen Hemophilia Inc.


07/07/16
20160194395 

Fusion proteins and their related methods


The present invention concerns a family of nucleic acids, polypeptides and cloning vectors which direct expression of fusion proteins that can mimic aggregated igg (aig) and immune complex function with respect to their interactions with fcγr and which allow for the inclusion and targeting of a second protein domain to cells expressing fcγr. This was accomplished by expressing multiple linear copies of the hinge and ch2 domains (hch2) of human igg1 fused to the framework region of human igg1.
Iterative Therapeutics, Inc.


07/07/16
20160194367 

Immunogenic peptides and their use in immune disorders


The present invention provides novel peptides and homologues thereof. The peptides of the invention comprise (i) a t-cell epitope of an antigen (self or non-self) with a potential to trigger an immune reaction presented by a class ii major histocompatibility complex (mhc) determinant and recognised by cd4+ t cell more specifically of an allergen or auto-antigen, coupled, optionally through the use of a linker to (ii) an amino acid sequence having a reducing activity, such as a thioreductase sequence.
Katholieke Universiteit Leuven


07/07/16
20160194366 

Applications of an immune system-released activating agent (israa)


The present invention relates to applications of an immune system-released activating agent (israa) polypeptide, which is induced by a nervous stimulus and which has been found to mediate the transmission of signals between the immune system and the nervous system following an immune challenge. The israa polypeptide is for use in a method of treatment of patients with immunodeficiency, immunosuppression or autoimmune disease; cancer; neurologic diseases and disorders; or muscular diseases and disorders..
Arabian Gulf University


07/07/16
20160194338 

Substituted tetrahydrocarbazole and carbazoles carboxamide compounds


R1 is f, cl, —cn, or —ch3; r2 is c1 or —ch3; r3 is —c(ch3)2oh or —ch2ch2oh; ra is h or —ch3; each rb is independently f, cl, —ch3, and/or —och3; and n is zero, 1, or 2. Also disclosed are methods of using such compounds as inhibitors of bruton's tyrosine kinase (btk), and pharmaceutical compositions comprising such compounds.

07/07/16
20160194329 

Therapeutically active pyrazolo-pyrimidine derivatives


A series of pyrazolo[3,4-d]pyrimidine derivatives that are substituted at the 4-position by a diaza monocyclic, bridged bicyclic or spirocyclic moiety, are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases and malaria; and organ and cell transplant rejection.. .
Katholieke Universiteit Leuven, K.u.leuven R&d


07/07/16
20160194308 

Novel piperidinyl benzoimidazole derivatives as mpges-1 inhibitors


The compounds 1-(5-chloro-6-methyl-1-(6-(trifluoromethyl)pyridin-2-yl)-1h-benzo[d]imidazol-2-yl)-n-((3s,4r)-4-hydroxytetrahydrofuran-3-yl)piperidine-4-carboxamide and 1-(6-chloro-5-methyl-1-(6-(trifluoromethyl)pyridin-2-yl)-1h-benzo[d]imidazol-2-yl)-n-((3s,4r)-4-hydroxytetrahydrofuran-3-yl)piperidine-4-carboxamide, as well as pharmaceutically acceptable salts thereof, and a pharmaceutical composition comprising any one of these compounds. The compound are useful for the treatment and/or prevention of a disorder selected from an inflammatory disease; an autoimmune disease; pain; a breathing disorder; cancer; a cardiovascular disease; a neurodegenerative disease; a bone disease; a disorder due to familial adenomatous polyposis (fap) condition; overactive bladder; fever; and inflammation-related anorexia..
Novasaid Ab


07/07/16
20160193350 

Phosphorylcholine conjugates and uses thereof


The present invention provides phosphorylcholine (pc)-conjugates and pharmaceutical compositions, particularly vaccines comprising same for the prevention or treatment of autoimmune diseases. In particular, the pc-conjugates of the present invention are effective in preventing or treating autoimmune diseases associated with pathological inflammation..
Tel Hashomer Medical Research Infrastructure And Services Ltd.


07/07/16
20160193257 

Human-derived bacteria that induce proliferation or accumulation of regulatory t cells


Species of human-derived bacteria belonging to the clostridia class have been shown to induce accumulation of regulatory t cells (treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases..
School Corporation, Azabu Veterinary Medicine Educational Institution


07/07/16
20160193256 

Human-derived bacteria that induce proliferation or accumulation of regulatory t cells


Species of human-derived bacteria belonging to the clostridia class have been shown to induce accumulation of regulatory t cells (treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases..
School Corporation, Azabu Veterinary Medicine Educational Institution


06/30/16
20160187351 

Method for the absolute quantification of naturally processed hla-restricted cancer peptides


The present invention relates to a method for the absolute quantification of naturally processed hla-restricted cancer peptides, i.e. The determination of the copy number of peptide(s) as presented per cell.

06/30/16
20160186178 

Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use


Aspects of the invention relate to spherical nucleic acid-based constructs and related methods and compositions thereof. The compositions of the invention are useful for activating agonists of nucleic acid interacting complexes, such as tlrs, stimulating an immune response, and treating diseases such as infectious disease, cancer, allergies, allergic diseases, and autoimmune disease.

06/30/16
20160185857 

Novel anti-fc-gamma receptor iib antibodies and uses thereof


The present invention provides an anti-fcyriib antibodies which, in comparison to prior art antibodies, markedly increase itim phosphorylation of fcyriib and can thus be used for the treatment or prophylaxis of autoimmune diseases.. .

06/30/16
20160185840 

Rna-coded antibody


The present application describes an antibody-coding, non-modified or modified rna and the use thereof for expression of this antibody, for the preparation of a pharmaceutical composition, in particular a passive vaccine, for treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, autoimmune diseases, virus diseases and monogenetic diseases, e.g. Also in gene therapy.

06/30/16
20160185771 

Conjugate of benzofuranone and indole or azaindole, and preparation and uses thereof


The present invention relates to an oxo indirubin or isoindigo derivative, an oxo aza indirubin or isoindigo derivative, and their optical isomers, racemes, cis/trans isomers and pharmaceutically acceptable salts, which can be used for preparing a drug for treating or preventing diseases such as glucose metabolic disorder, inflammatory or autoimmune disease, neurodegenerative disease, a mental illness, tissue proliferation disease or tumors.. .

06/30/16
20160185756 

Substituted benzimidazoles and benzopyrazoles as ccr(4) antagonists


Benzimidazole, benzopyrazole and benzotriazole compounds are provided which bind to ccr(4) and are useful for the treatment of diseases such as allergic diseases, autoimmune diseases, graft rejection and cancer.. .

06/30/16
20160184329 

Formulations and compositions of vitamin d analogs for treating and preventing cancer and other diseases


This invention is for formulations of analogs of the non-toxic and inert vitamin d3, its non-toxic and mostly inert pre-hormone and its toxic and biologically active hormone, and for using these formulations for preventing and treating certain cancers such as breast, prostate, ovarian, kidney, renal and other cancers, vitamin d deficiency, autoimmune disease such as multiple sclerosis, hypertension, osteoporosis, bone diseases, rickets, psoriasis and infectious diseases. This invention also discloses compositions of the analogs of the non-toxic and inert vitamin d3 and the non-toxic and mostly inert vitamin d3 pre-hormone..

06/30/16
20160184307 

Heterocyclyl pyrimidine analogues as tyk2 inhibitors


Wherein r, r1, x1 to x5 have the meaning as cited in the description and the claims. Said compounds are useful as tyk2 inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases.

06/30/16
20160184262 

4-methylumbelliferone treatment for immune modulation


Compositions for treating autoimmune, allergic, or atopic disease comprising a compound that inhibits hyaluronan synthesis and a pharmaceutically acceptable carrier are described. In some embodiments, the compound that inhibits hyaluronan synthesis is 4-methylumbelliferone or a metabolite of 4-methylumbelliferone.

06/30/16
20160184234 

Eluting matrix and uses thereof


Cxcl12 polypeptide eluting matrices encapsulating at least one cell are described for use in the treatment of autoimmune disorders.. .



Autoimmune topics: Autoimmune, Immune Disease, Autoimmune Disease, Immune Diseases, Autoimmune Diseases, Transplant, Immune Disorder, Autoimmune Disorder, Autoimmune Disorders, Infectious, Infectious Disease, Inflammatory Disease, Type 1 Diabetes, Proliferative Disorder, Recurrence

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Autoimmune for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Autoimmune with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.3049

5313

1 - 1 - 104